Article de Périodique
Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (Ecstasy) (2002)
Auteur(s) :
RICAURTE, G. A. ;
YUAN J. ;
HATZIDIMITRIOU G. ;
CORD, B. J. ;
McCANN, U. D.
Année
2002
Page(s) :
2260-2263
Langue(s) :
Anglais
Refs biblio. :
34
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
MDMA-ECSTASY
;
DOPAMINE
;
TOXICITE
;
NEUROLOGIE
;
SEROTONINE
;
EFFET SECONDAIRE
;
USAGE RECREATIF
;
MODELE ANIMAL
;
MALADIE DE PARKINSON
Note générale :
Cet article a fait l'objet d'une rétractation dans le numéro de Science du 12 sept. 2003 :
- Paper on toxic party drug is pulled over vial mix-up. Holden C. Science 2003;301(5639):1454.
- Retraction. Science 2003;301(5639):1479.
Letter to the Editor: MDMA ("ecstasy") and neurotoxicity. Mithoefer M, Jerome L, Doblin R. Science, 2003,300(5625):1504-5; author reply 1504-5.
- Paper on toxic party drug is pulled over vial mix-up. Holden C. Science 2003;301(5639):1454.
- Retraction. Science 2003;301(5639):1479.
Letter to the Editor: MDMA ("ecstasy") and neurotoxicity. Mithoefer M, Jerome L, Doblin R. Science, 2003,300(5625):1504-5; author reply 1504-5.
Résumé :
The prevailing view is that the popular recreational drug 3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy") is a selective serotonin neurotoxin in animals and possibly in humans. Nonhuman primates exposed to several sequential doses of MDMA, a regimen modeled after one used by humans, developed severe brain dopaminergic neurotoxicity, in addition to less pronounced serotonergic neurotoxicity. MDMA neurotoxicity was associated with increased vulnerability to motor dysfunction secondary to dopamine depletion. These results have implications for mechanisms of MDMA neurotoxicity and suggest that recreational MDMA users may unwittingly be putting themselves at risk, either as young adults or later in life, for developing neuropsychiatric disorders related to brain dopamine and/or serotonin deficiency.
Affiliation :
The Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Fransisco, CA, USA
Historique